Daiichi Sankyo Development

Daiichi Sankyo Development is the European clinical development arm of Daiichi Sankyo, a leading global pharmaceutical company headquartered in Japan. Based in the United Kingdom, the entity is responsible for the strategic planning and management of clinical trials across Europe, focusing heavily on the company's oncology pipeline. It plays a pivotal role in advancing the proprietary DXd antibody-drug conjugate (ADC) technology platform through various stages of clinical research. The organization collaborates closely with global teams to secure regulatory approvals and bring innovative therapies to patients with cancer and other serious diseases. Its expertise spans clinical operations, regulatory affairs, and drug safety, ensuring that novel treatments meet stringent international standards.